<DOC>
	<DOCNO>NCT00859482</DOCNO>
	<brief_summary>Natalizumab humanize monoclonal antibody direct Very Late Activation Antigene 4 ( VLA-4 ) potent effect disease activity multiple sclerosis ( MS ) . A blockade VLA-4 natalizumab may interfere autoimmunological process also central nervous system ( CNS ) immune surveillance .</brief_summary>
	<brief_title>Differential Immune Effects Natalizumab</brief_title>
	<detailed_description>Longitudinal ex vivo vitro study determine effect natalizumab frequency distinct immune cell frequency suppressive function natural CD4+CD25+ regulatory T cell ( Tregs ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>relapse remit MS indication natalizumab treatment disease modify agent within 2 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>natalizumab</keyword>
	<keyword>multiple sclerosis</keyword>
</DOC>